What is the combination of Cabenuva?

Cabenuva is a long-acting injectable regimen specifically designed for the treatment of HIV. The combination that makes up Cabenuva consists of Cabotegravir and rilpivirine.

Cabotegravir is an integrase inhibitor that prevents the HIV virus from integrating its genetic material into the host cell's DNA, thereby stopping the replication of the virus. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the reverse transcriptase enzyme, another crucial step in the HIV replication cycle. Together, these medications work synergistically to effectively suppress viral load.

While there are other combinations in the treatment of HIV, such as lamivudine with zidovudine or abacavir with lamivudine, these are not part of Cabenuva's formulation. The specific pairing of Cabotegravir and rilpivirine in Cabenuva allows for a unique and effective approach to maintaining viral suppression with less frequent dosing compared to traditional oral antiretroviral treatments, which enhances patient adherence and convenience.